Back to search

Japan· JP-6429005F1026

メベンダゾール錠100(ヤンセンファーマ)

A mebendazole product containing メベンダゾール, registered in Japan by ヤンセンファーマ, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

On Japan’s NHI price listATC P02CA01

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedメベンダゾール錠100(ヤンセンファーマ)ATCP02CA01REGISTER NO.JP-6429005F1026PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Mebendazole is registered in 14 of 19 countries.

Countries holding a registration under ATC P02CA01 (mebendazole), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 7 of them publish a price we can compare per daily dose

Mebendazole · ATC P02CA01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
メベンダゾール
Manufacturer
ヤンセンファーマ
Country
Japan (JP)
ATC code
P02CA01
ATC class
Mebendazole
Defined daily dose
0.2 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

10 interactions on record for mebendazole.

Graded by severity as the source publishes them — 9 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Mebendazole · interactions on record

10 records

  • 9 moderate
  • 1 minor

Most severe, free to view

  • MetronidazoleJ01XD01moderate
  • RitonavirJ05AE03moderate
  • PhenobarbitalN03AA02moderate
  • PrimidoneN03AA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d083004a-bc0e-42cb-9cfb-57dcb55976b2
GET /v1/drugs/d083004a-bc0e-42cb-9cfb-57dcb55976b2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "100mg1錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "6429005F1026",
  "category": "内用薬",
  "price_yen": 366.4,
  "generic_name": "メベンダゾール",
  "product_name_jp": "メベンダゾール錠100(ヤンセンファーマ)",
  "therapeutic_class": "6429",
  "transitional_expiry": null
}

See everything about mebendazole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.